Case 2:08-cv-03573-MRP -JEM	Document 290-1	Filed 07/27/10	Page 1 of 2	Page ID
	#· <b>7</b> 002		_	•

1 2 3 4 5	Mark A. Pals, P.C. (pro hac vice) mpals@kirkland.com Marcus E. Sernel (pro hac vice) msernel@kirkland.com KIRKLAND & ELLIS LLP 300 North LaSalle Chicago, IL 60654 (312)862-2000 (o); (312)862-2200 (f)  Daralyn J. Durie (SBN 169825) ddurie@durietangri.com	David I. Gindler (SBN 117824) dgindler@irell.com Joseph M. Lipner (SBN 155735) jlipner@irell.com IRELL & MANELLA, LLP 1800 Avenue of the Stars Los Angeles, CA 90067 (310)277-1010 (o); (310)203-7199 (f) Attorneys for CITY OF HOPE			
7 8 9	Mark Lemley (SBN 155830) mlemley@durietangri.com DURIE TANGRI LLP 217 Leidesdorff Street San Francisco, CA 94111 (415)362-6666 (o); (415)236-6300 (f)				
10	Attorneys for GENENTECH, INC.				
11	CENTRAL DISTRICT OF CALIFORNIA				
12	WESTERN DIVISION				
13	CENTOCOR ORTHO BIOTECH, INC.,	Case No. CV 08-03573 MRP (CTx)			
14	Plaintiff,	The Honorable Mariana R. Pfaelzer			
15	V	[PROPOSED] ORDER			
16	GENENTECH, INC. AND CITY OF HOPE,	GRANTING GENENTECH, INC.'S AND CITY OF HOPE'S CROSS MOTION FOR			
17	Defendants.	SUMMARY ADJUDICATION			
18 19	GENENTECH, INC. AND CITY OF HOPE,				
20	Counter-Plaintiffs (				
21	V.				
22	CENTOCOR ORTHO BIOTECH, INC.,				
23	Counter-Defendant AND				
24	GLOBAL PHARMACEUTICAL				
25	SUPPLY GROUP, LLC, CENTOCOR BIOLOGICS, LLC, AND JOM PHARMACEUTICAL SERVICES, INC.,	Date: August 17, 2010			
26		Time: TBD Ctrm: 12			
27	Third-party Defendants.	Judge: Honorable Mariana R. Pfaelzer			

Having considered Genentech, Inc.'s and City of Hope's Cross Motion for Summary Adjudication, any opposition thereto, and the arguments of the parties for and against the Motion, and good cause showing,

## IT IS HEREBY ORDERED THAT:

- 1. Genentech, Inc. and City of Hope's Cross Motion for Summary Adjudication is GRANTED.
- 2. The processes used to produce ReoPro, Remicade, Simponi, and Stelara include the step of "independently expressing a first DNA sequence encoding at least the variable domain of the immunoglobulin heavy chain and a second DNA sequence encoding at least the variable domain of the immunoglobulin light chain so that said immunoglobulin heavy and light chains are produced as separate molecules in said single host cell" as recited in claim 33 of U.S. Patent No. 6,331,415.

IT IS SO ORDERED

Dated:	

Hon. Mariana R. Pfaelzer United States District Judge